These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3472024)

  • 1. [Serum CA 15.3-ELSA in non-tumor pathology].
    Ruibal A; Genollá J; Rosell M; Moragas G
    Med Clin (Barc); 1987 Mar; 88(11):476. PubMed ID: 3472024
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary results on the use of Ca 15-3 in malignant ovarian pathology.
    Ferdeghini M; Gadducci A; Romagnoli S; Bartolini T; Facchini V; Scatena P; Bianchi R; Fioretti P
    J Nucl Med Allied Sci; 1987; 31(4):299-302. PubMed ID: 3481812
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum BCM in patients with nontumorous diseases. Preliminary results].
    Allende MT; Vizoso F; Sampedro A; Ruibal A
    Rev Clin Esp; 1990 Oct; 187(5):254-5. PubMed ID: 2102542
    [No Abstract]   [Full Text] [Related]  

  • 4. [CA 19-9 enzyme immunoassay].
    Ota H; Odani H; Watanabe H; Satomura Y; Takemori Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
    Gan No Rinsho; 1986 Aug; 32(9):993-7. PubMed ID: 3528560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of a new tumor marker (CA 19-9) in the differential diagnosis of pathological changes in the pancreas detected by ultrasonic diagnosis].
    Bohár L; Szilvási I; Bodorné N; Varsányi N; Barda L; Sarkadi G
    Orv Hetil; 1985 Oct; 126(41):2525-7. PubMed ID: 3900874
    [No Abstract]   [Full Text] [Related]  

  • 6. [Serum CA 1,25 in patients with non-ovarian tumors. Evidence of a relation between the increase of the antigen and hepatic disease].
    Ruibal A; Siurana R; Encabo G; Cuartero A
    Med Clin (Barc); 1985 Mar; 84(9):376-7. PubMed ID: 3857424
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients.
    Souchon R; Koppenhagen K; Souchon MF; Matthes M; Boese-Landgraf J; Fitzner R; Baer U
    Cancer Detect Prev; 1985; 8(1-2):101-9. PubMed ID: 3864534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological significance of tumor marker].
    Ochi Y
    Rinsho Byori; 1985 Aug; 33(8):831-8. PubMed ID: 3908745
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
    Olsson NO; Crimet-Montange D; Martin F
    Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum CA-125 level in patients with gynecologic tumors].
    Abe Y; Ueda G; Yamasaki M; Inoue M; Hiramatsu K; Inoue Y; Saito J; Nishino T
    Rinsho Byori; 1984 Dec; 32(12):1350-4. PubMed ID: 6597876
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical evaluation of a cancer antigen CA 125 associated with ovarian cancer. II. Serum CA 125 levels in normal pregnancy].
    Suzuki M; Sekiguchi I; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1985 Jan; 33(1):73-6. PubMed ID: 3857365
    [No Abstract]   [Full Text] [Related]  

  • 12. [Incidence of CA 125 antigen in the blood of women with ovarian carcinoma].
    Tosner J; Lacinová V; Louda B; Vanásek J
    Cesk Gynekol; 1987 Nov; 52(9):681-4. PubMed ID: 3482173
    [No Abstract]   [Full Text] [Related]  

  • 13. [Serum carbohydrate 19-9 Tm and bronchial cancer. Comparative study with another tumor marker, carcinoembryonic antigen].
    Bisset JP; Kleisbauer JP; Roux F; Treffot MJ
    Pathol Biol (Paris); 1985 Jun; 33(6):672-6. PubMed ID: 3900886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of CA 19-9 radioimmunoassay].
    Toya D; Takemori Y; Kidani H; Yoneshima M; Hattori N; Sawabu N
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):509-14. PubMed ID: 6584087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
    Klapdor R; Greten H
    Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
    [No Abstract]   [Full Text] [Related]  

  • 17. [CA 19-9 in early cancers of the bronchi. Comparison with the carcinoembryogenic antigen].
    Vindimian M; Lafitte JJ; Wattre P
    Biomed Pharmacother; 1987; 41(4):191-5. PubMed ID: 3476162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
    Crombach G; Zippel HH; Würz H
    Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Carbohydrate antigen (CA-19-9) in the blood serum of patients with benign and malignant liver diseases].
    Ametov AS; Kasatkin IuN; Mit'kov VV; Gur'eva IV
    Med Radiol (Mosk); 1985 Mar; 30(3):39-41. PubMed ID: 3856723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of a cancer antigen, CA 125, associated with ovarian cancer. I. Technical investigation and the reference value].
    Sakurabayashi I; Kawai T; Suzuki M; Tamada T; Sato K; Yonezawa M
    Rinsho Byori; 1984 Dec; 32(12):1345-9. PubMed ID: 6597875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.